Clinical Trial Detail

NCT ID NCT02632344
Title Study of Anti-PD-1 Therapy for HPV-associated Recurrent Respiratory Papilloma Patients With Laryngeal, Tracheal and/or Pulmonary Involvement
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Massachusetts General Hospital
Indications

papilloma

Therapies

Pembrolizumab

Age Groups: adult

No variant requirements are available.